Reference(s)
Click here to return to the Reference Table

Descriptor: Reviews


Acute Myelogenous Leukemia

Adult T Cell Leukemia

Bladder

Breast

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1210
Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 3, 14-25 (2012)
PubMed link      E-mail link

Reference Number: 1543
Al Moustafa AE. Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer. Cell Adh Migr. 7, 424-5 (2013)
PubMed link      E-mail link

Reference Number: 1641
Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets. 18, 999-1009 (2014)
PubMed link      E-mail link

Reference Number: 1667
Liu S. HGF-MET as a breast cancer biomarker. Aging (Albany NY). 7, 150-1 (2015)
PubMed link      E-mail link

Reference Number: 1861
Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 17, 52 (2015)
PubMed link      E-mail link

Cervical

Cholangiocarcinoma

Reference Number: 760
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14, 2990-4 (2008)
PubMed link      E-mail link

Reference Number: 774
Kuroki T, Tajima Y, Kanematsu T Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepatobiliary Pancreat Surg. 12, 463-6 (2005)
PubMed link      E-mail link

Chronic Myeloid Leukemia

Colorectal

Reference Number: 750
Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 41, 2356-9 (2009)
PubMed link      E-mail link

Reference Number: 1681
Gao H, Guan M, Sun Z, Bai C. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumour Biol. 36, 515-20 (2015)
PubMed link      E-mail link

Endometrial

Reference Number: 1726
Li M, Xin X, Wu T, Hua T, Wang H. HGF and c-Met in pathogenesis of endometrial carcinoma. Front Biosci (Landmark Ed). 20, 635-43 (2015)
PubMed link      E-mail link

Esophogeal

Reference Number: 1321
Hong TS, Wo JY, Kwak EL. Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol. 23, 31-7 (2013)
PubMed link      E-mail link

Reference Number: 1634
Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 5, 2866-80 (2014)
PubMed link      E-mail link

Gastric

Reference Number: 382
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 7, 3499-508 (2008)
PubMed link      E-mail link

Reference Number: 621
Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 26, 121 (2010)
PubMed link      E-mail link

Reference Number: 1520
Teng L, Lu J. cMET as a potential therapeutic target in gastric cancer (Review). Int J Mol Med. 32, 1247-54 (2013)
PubMed link      E-mail link

Reference Number: 1596
Al-Batran SE, Werner D Recent advances and future trends in the targeted therapy of metastatic gastric cancer. Expert Rev Gastroenterol Hepatol. 8, 555-69 (2014)
PubMed link      E-mail link

Reference Number: 1613
Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 5, 2866-80 (2014)
PubMed link      E-mail link

Reference Number: 1693
Venerito M, Nardone G, Selgrad M, Rokkas T, Malfertheiner P. Gastric cancer--epidemiologic and clinical aspects. Helicobacter. 19, Suppl 1:32-7 (2014)
PubMed link      E-mail link

Reference Number: 1711
Thiel A, Ristimäki A. Targeted therapy in gastric cancer. APMIS. 123, 365-72 (2015)
PubMed link      E-mail link

Reference Number: 1728
Abdel-Rahman O Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther. 15,235-45 (2015)
PubMed link      E-mail link

Reference Number: 1742
Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. c-Met targeting in advanced gastric cancer: An open challenge. Cancer Lett. 365, 30-6 (2015)
PubMed link      E-mail link

Reference Number: 1837
Aprile G, Ongaro E, Del Re M, Lutrino SE, Bonotto M, Ferrari L, Rihawi K, Cardellino GG, Pella N, Danesi R, Fasola G. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Crit Rev Oncol Hematol. 95, 165-78 (2015)
PubMed link      E-mail link

Reference Number: 1854
Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 19, 1046-55 (2014)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 677
Moriyama T, Kataoka H, Koono M, Wakisaka S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med. 3, 531-6 (1999)
PubMed link      E-mail link

Reference Number: 775
Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 7, 436-51 (2005)
PubMed link      E-mail link

Reference Number: 888
Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 17, 517-30 (1999)
PubMed link      E-mail link

Reference Number: 1504
Boccaccio C, Comoglio PM. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res. 73, 3193-9 (2013)
PubMed link      E-mail link

Head and Neck

Reference Number: 766
De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci. 13, 2516-26 (2008)
PubMed link      E-mail link

Reference Number: 1048
Lau PC, Chan AT. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs. 22, 665-73 (2011)
PubMed link      E-mail link

Reference Number: 1781
Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacol Ther. 143, 337-49 (2014)
PubMed link      E-mail link

Kaposi's Sarcoma

Kidney

Reference Number: 737
Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 7, 277-85 (2010)
PubMed link      E-mail link

Reference Number: 742
Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 61, 329-43 (2010)
PubMed link      E-mail link

Reference Number: 752
Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 9, 785-93 (2009)
PubMed link      E-mail link

Reference Number: 783
Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 4, 855-68 (2004)
PubMed link      E-mail link

Reference Number: 788
Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 170(6 Pt 1), 2163-72 (2003)
PubMed link      E-mail link

Reference Number: 885
Sánchez P, Calvo E, Durán I. Non-clear cell advanced kidney cancer: is there a gold standard? Anticancer Drugs. 22, Suppl 1:S9-14 (2011)
PubMed link      E-mail link

Reference Number: 886
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 10, 658-64 (2010)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1346
Logan TF. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep. 15, 83-90 (2013)
PubMed link      E-mail link

Reference Number: 1547
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 21, 81-90 (2014)
PubMed link      E-mail link

Reference Number: 1605
Fay AP, Signoretti S, Choueiri TK. MET as a target in papillary renal cell carcinoma. Clin Cancer Res. 20, 3361-3 (2014)
PubMed link      E-mail link

Leiomyosarcoma

Liver

Reference Number: 746
Osada S, Yoshida K. Application of biological study for met expression to cancer therapy. Anticancer Agents Med Chem. 10, 58-63 (2010)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1193
Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 39, 493-502 (2012)
PubMed link      E-mail link

Reference Number: 1357
Goyal L1, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 19, 2310-8 (2013)
PubMed link      E-mail link

Reference Number: 1369
Marquardt JU, Thorgeirsson SS. Linking MLL and the HGF-MET signaling pathway in liver cancer. J Clin Invest. 123, 2780-3 (2013)
PubMed link      E-mail link

Reference Number: 1690
Rota Caremoli E, Labianca R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin Investig Drugs. 23, 1563-74 (2014)
PubMed link      E-mail link

Reference Number: 1789
Johnson PJ. How do mechanisms of hepatocarcinogenesis (HBV, HCV, and NASH) affect our understanding and approach to HCC? Am Soc Clin Oncol Educ Book. (2013)
PubMed link      E-mail link

Reference Number: 1855
Choi KJ, Baik IH, Ye SK, Lee YH. Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions. Biol Pharm Bull. 38, 986-91 (2015)
PubMed link      E-mail link

Reference Number: 1856
Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 21, 5445-53 (2015)
PubMed link      E-mail link

Lung

Reference Number: 740
Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 6, 239-47 (2010)
PubMed link      E-mail link

Reference Number: 741
Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 4, 146-52 (2010)
PubMed link      E-mail link

Reference Number: 756
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79 (2009)
PubMed link      E-mail link

Reference Number: 790
Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol. 22, 147-65 (2003)
PubMed link      E-mail link

Reference Number: 794
Maulik G, Kijima T, Salgia R. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 74, 113-25 (2003)
PubMed link      E-mail link

Reference Number: 879
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 958
Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11, 1477-90 (2010)
PubMed link      E-mail link

Reference Number: 973
Bonanno L, Jirillo A, Favaretto A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr Drug Targets. 12, 922-33 (2011)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1180
Ruppert AM, Beau-Faller M, Belmont L, Lavolé A, Gounant V, Cadranel J, Wislez M. [A simple view on lung cancer biology: the MET pathway]. Rev Mal Respir. 28, 1241-9 (2011)
PubMed link      E-mail link

Reference Number: 1192
Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 12, 519-28 (2012)
PubMed link      E-mail link

Reference Number: 1264
Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Rev Anticancer Ther. 12, 1299-312 (2012)
PubMed link      E-mail link

Reference Number: 1332
Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev. 31, 807-14 (2012)
PubMed link      E-mail link

Reference Number: 1356
Alamgeer M1, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 13, 394-401 (2013)
PubMed link      E-mail link

Reference Number: 1416
Gridelli C1, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 40, 300-6 (2014)
PubMed link      E-mail link

Reference Number: 1497
Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist. 18, 115-22 (2013)
PubMed link      E-mail link

Reference Number: 1538
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 89, 284-99 (2014)
PubMed link      E-mail link

Reference Number: 1574
Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 73, 2031-51 (2013)
PubMed link      E-mail link

Reference Number: 1637
Capelletti M, Gelsomino F, Tiseo M. MET and ALK as targets for the treatment of NSCLC. Curr Pharm Des. 20, 3914-32 (2014)
PubMed link      E-mail link

Reference Number: 1678
Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 9, e107677 (2014)
PubMed link      E-mail link

Reference Number: 1687
Gozdzik-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R. C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol. 15, 670-82 (2014)
PubMed link      E-mail link

Reference Number: 1716
Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respir Investig. 52, 82-91 (2014)
PubMed link      E-mail link

Reference Number: 1757
Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets. 15, 1284-92 (2014)
PubMed link      E-mail link

Reference Number: 1819
Pérez-Ramírez C, Cañadas-Garre M, Jiménez-Varo E, Faus-Dáder MJ, Calleja-Hernández MÁ. MET: a new promising biomarker in non-small-cell lung carcinoma. Pharmacogenomics. 16, 631-47 (2015)
PubMed link      E-mail link

Reference Number: 1821
Li A, Gao HF, Wu YL. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin Ther Targets. 19, 663-74 (2015)
PubMed link      E-mail link

Reference Number: 1835
Loong HH, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncol. 11, 735-45 (2015)
PubMed link      E-mail link

Reference Number: 1843
Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus? Expert Rev Anticancer Ther. 15, 487-9 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 887
Mahtouk K, Tjin EP, Spaargaren M, Pals ST. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 1806, 208-19 (2010)
PubMed link      E-mail link

Reference Number: 958
Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11, 1477-90 (2010)
PubMed link      E-mail link

Melanoma

Mesothelioma

Reference Number: 756
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79 (2009)
PubMed link      E-mail link

MFH/Fibrosarcoma

Multiple Myeloma

Reference Number: 887
Mahtouk K, Tjin EP, Spaargaren M, Pals ST. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 1806, 208-19 (2010)
PubMed link      E-mail link

Reference Number: 890
Børset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma. 32, 249-56 (1999)
PubMed link      E-mail link

Reference Number: 1875
Gambella M, Palumbo A, Rocci A. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy? Expert Rev Mol Diagn. 15, 881-93 (2015)
PubMed link      E-mail link

Nasopharyngeal

Osteosarcoma

Ovarian

Reference Number: 755

Zhou HY, Pon YL, Wong AS. HGF/MET signaling in ovarian cancer. Curr Mol Med. 8, 469-80 (2008)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1712
Yamashita Y Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy. Jpn J Clin Oncol. 45, 405-7 (2015)
PubMed link      E-mail link

Pancreas/Gall Bladder

Reference Number: 1660
Delitto D, Vertes-George E, Hughes SJ, Behrns KE, Trevino JG. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol. 20, 8458-70 (2014)
PubMed link      E-mail link

Reference Number: 1698
Fitzgerald TL, McCubrey JA. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul. 56, 45-50 (2014)
PubMed link      E-mail link

Prostate

Reference Number: 785
Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 91, 31-67 (2004)
PubMed link      E-mail link

Reference Number: 1173
Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem. 4, 107-19 (2012)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1325
Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 19, 90-8 (2013)
PubMed link      E-mail link

Reference Number: 1640
Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 33, 581-94 (2014)
PubMed link      E-mail link

Reference Number: 1652
Ojemuyiwa MA, Madan RA, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs. 19, 459-70 (2014)
PubMed link      E-mail link

Rhabdomyosarcoma

Synovial Sarcoma

Thyroid

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1130
Almeida MQ, Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol. 24, 229-34 (2012)
PubMed link      E-mail link

Wilms' Tumor